Most COVID-19 trial preprints were eventually published, and the conclusions mostly stayed the same

Publicly released:
International

During the pandemic, preprints helped make clinical trial results available as quickly as possible, and now researchers have found that most preprints of COVID-19 clinical trials ended up being published in a peer-reviewed journal. The researchers found that preprint studies with smaller numbers of participants (sample size) and higher risk of bias were less likely to be published. They also found that, although there were differences in the reported outcomes, analyses and results between the preprint and final publication, the main conclusions remained the same for the majority of studies.

Media release

From:

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).
Journal/
conference:
JAMA Network Open
Research:Paper
Organisation/s: Queen’s University, Canada
Funder: Dr Loeb reported serving on advisory boards for Sanofi, Pfizer, Medicago, Merck, Seqirus, Paladin Labs, and GlaxoSmithKline aswell as on committees for Medicago, CanSino Biologics (data safety and monitoring), the National Institutes of Health, and theWorld Health Organization Essential Medicines List AntibioticWorking Group outside the submitted work. No
Media Contact/s
Contact details are only visible to registered journalists.